After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078) or (B) Mouse IgG2AIsotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B)." class="big_lightbox" target="_blank">
2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078). The ND50 is typically 0.2-0.8 µg/mL." class="big_lightbox" target="_blank">
2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB2/CD85d/ILT4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2078). The ND50 is typically 0.3-1.0 µg/mL." class="big_lightbox" target="_blank">
VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surface. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox" target="_blank">
FAB3832P) and either (A) Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078R) or (B) Mouse IgG2A Isotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox" target="_blank">
2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line) as measured by Calcein AM. Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human LILRB2/CD85d/ILT4 Monoclonal Antibody (Catalog # MAB2078R). The ND50 is typically0.15-0.9 µg/mL." class="big_lightbox" target="_blank">
9795-AN) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag (Catalog # AVI2078) binds with an ED50 of 10-80 ng/mL." class="big_lightbox" target="_blank">
LILRB2, also known as Leukocyte immunoglobulin-like receptor subfamily B member 2, has 2 isoforms, a 598 amino acid isoform that is 65 kDa and a 597 amino acid isoform that is approx. 65 kDa; expressed on monocytes and B-cells, and at lower levels on dendritic cells and in natural killer (NK) cells; as a receptor binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response; also competes with CD8A for binding to class I MHC antigens and inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. Disease research is currently being performed with relation to LILRB2 and herpes simplex, chronic lymphocytic leukemia, lymphocytic leukemia, and leukemia. Interactions with this protein have been shown to involve PTPN6, FCGR1A, HLA-F, HLA-G, CD1D and other proteins in osteoclast differentiation, immune-regulatory interactions between a lymphoid and a non-lymphoid cell, adaptive immune system, and immune system pathways.
![Flow Cytometry ILT4/CD85d/LILRB2 Antibody (287219) [Unconjugated]](http://images.novusbio.com/images/antibody/LILRB2_MAB2078_Flow_Cytometry_18220.jpg)
![Neutralization ILT4/CD85d/LILRB2 Antibody [Unconjugated]](http://images.novusbio.com/images/antibody/ILT4_AF2078_Block_Neutralize_8814.jpg)
![Flow Cytometry ILT4/CD85d/LILRB2 Antibody (287219R) [Unconjugated]](http://images.novusbio.com/images/antibody/LILRB2_MAB2078R_Flow_Cytometry_23562.jpg)
![Binding Activity ILT4/CD85d/LILRB2 [Unconjugated]](http://images.novusbio.com/fullsize/protein/LILRB2_2078T4_2303.jpg)
![Binding Activity ILT4/CD85d/LILRB2 [Biotin]](http://images.novusbio.com/images/avi2078_recombinant-human-lilrb2-cd85d-ilt4-fc-avi-tag-protein-cf-sds-page-91220219137.jpg)
![Neutralization ILT4/CD85d/LILRB2 Antibody (287219) [Unconjugated]](http://images.novusbio.com/images/antibody/ILT4_MAB2078_Block_Neutralize_9063.jpg)
![Immunohistochemistry ILT4/CD85d/LILRB2 Antibody [Unconjugated]](http://images.novusbio.com/images/af2078_human-lilrb2-cd85d-ilt4-affinity-purified-polyclonal-ab-immunohistochemistry-4112022105023.jpg)
![Neutralization ILT4/CD85d/LILRB2 Antibody (287219R) [Unconjugated]](http://images.novusbio.com/images/antibody/LILRB2_MAB2078R_Block_Neutralize_23659.jpg)
![Bioactivity ILT4/CD85d/LILRB2 [Unconjugated]](http://images.novusbio.com/images/protein/LILRB2_8429T4_1266.jpg)
![SDS-Page ILT4/CD85d/LILRB2 [Unconjugated]](http://images.novusbio.com/fullsize/protein/LILRB2_8429T4_1343.jpg)
![SDS-Page ILT4/CD85d/LILRB2 [Biotin]](http://images.novusbio.com/fullsize/avi2078_recombinant-human-lilrb2-cd85d-ilt4-fc-avi-tag-protein-cf-sds-page-311202184422.jpg)
